(Q42744862)

6 November 2017

title

Inhibition of hepatitis C virus replication by semi-synthetic derivatives of glycopeptide antibiotics (English)

1 reference

6 November 2017

0 references

1 reference

5

1 reference

6 November 2017

Maria Preobrazhenskaya

7

1 reference

6 November 2017

Jan Paeshuyse

9

0 references

Johan Neyts

object named as

Johan Neyts

8

0 references

author name string

Susan Obeid

1

1 reference

6 November 2017

Svetlana S Printsevskaya

2

1 reference

6 November 2017

Eugenia N Olsufyeva

3

1 reference

6 November 2017

Kai Dallmeier

4

1 reference

6 November 2017

Fabien Zoulim

6

1 reference

6 November 2017

language of work or name

English

0 references

publication date

24 March 2011

1 reference

Journal of Antimicrobial Chemotherapy

6 November 2017

published in

1 reference

6 November 2017

volume

66

1 reference

6 November 2017

issue

6

1 reference

6 November 2017

page(s)

1287-1294

1 reference

Formulation and evaluation of a folic acid receptor-targeted oral vancomycin liposomal dosage form

6 November 2017

cites work

1 reference

12 December 2020

Antiviral activity of geneticin against dengue virus

1 reference

12 December 2020

Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose

1 reference

12 December 2020

Vancomycin, teicoplanin, and ramoplanin: synthetic and mechanistic studies

1 reference

12 December 2020

Antiviral therapy for hepatitis C virus: beyond the standard of care

1 reference

12 December 2020

Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs).

1 reference

12 December 2020

Interactions of oritavancin, a new lipoglycopeptide derived from vancomycin, with phospholipid bilayers: Effect on membrane permeability and nanoscale lipid membrane organization.

1 reference

12 December 2020

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

12 December 2020

Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics

1 reference

12 December 2020

HCV drug discovery aimed at viral eradication

1 reference

12 December 2020

Polycyclic peptide and glycopeptide antibiotics and their derivatives as inhibitors of HIV entry.

1 reference

12 December 2020

Robust production of infectious viral particles in Huh-7 cells by introducing mutations in hepatitis C virus structural proteins

1 reference

12 December 2020

New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin

1 reference

12 December 2020

Vancomycin resistance: decoding the molecular logic

1 reference

12 December 2020

Analysis of combinations of antiviral drugs and design of effective multidrug therapies

1 reference

12 December 2020

Antiretroviral activity of semisynthetic derivatives of glycopeptide antibiotics

1 reference

12 December 2020

Substituted imidazopyridines as potent inhibitors of HCV replication

1 reference

12 December 2020

Clinical trial results of peginterferons in combination with ribavirin

1 reference

12 December 2020

PEG IFN alfa-2a vs. alfa-2b: And the winner is …?

1 reference

12 December 2020

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

1 reference

12 December 2020

Structure-activity relationship studies of a series of antiviral and antibacterial aglycon derivatives of the glycopeptide antibiotics vancomycin, eremomycin, and dechloroeremomycin

1 reference

12 December 2020

Persistent Hepatitis C Virus Infection In Vitro: Coevolution of Virus and Host

1 reference

12 December 2020

Mixed-lipid storage disorder induced in macrophages and fibroblasts by oritavancin (LY333328), a new glycopeptide antibiotic with exceptional cellular accumulation

1 reference

12 December 2020

HCV NS5B polymerase inhibitors

1 reference

12 December 2020

Vancomycin vs teicoplanin in the treatment of Gram-positive infections: a pharmacoeconomic analysis in a Turkish University Hospital

1 reference

12 December 2020

Antiviral resistance and specifically targeted therapy for HCV (STAT-C).

1 reference

12 December 2020

Hepatitis C virus hijacks host lipid metabolism

1 reference

12 December 2020

Comparative In Vitro Anti-Hepatitis C Virus Activities of a Selected Series of Polymerase, Protease, and Helicase Inhibitors

1 reference

12 December 2020

Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors

1 reference

12 December 2020

Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development

1 reference

12 December 2020

Review article: specifically targeted anti-viral therapy for hepatitis C - a new era in therapy

1 reference

12 December 2020

Discovery of the hepatitis C virus

1 reference

12 December 2020

The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro

1 reference

12 December 2020

Membrane association of hepatitis C virus nonstructural proteins and identification of the membrane alteration that harbors the viral replication complex

1 reference

12 December 2020

Antiviral activity of geneticin against bovine viral diarrhoea virus

1 reference

12 December 2020

Glycopeptide derivatives

1 reference

12 December 2020

Identifiers

DOI

10.1093/JAC/DKR104

1 reference

6 November 2017

0 references

1 reference